RxDoctor Payments Data

Mohammad Iqbal, MD

Urology · Elizabethtown, KYNPI 1447211305

Payments from drug & device makers

$2,261in general payments, 2019–2025

Across 69 payments — averaging $32.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neotract Inc.$922
  • Neurocrine Biosciences, Inc.$261
  • Endo Pharmaceuticals Inc.$209
  • Astellas Pharma US Inc$155
  • Johnson & Johnson$138
  • Antares Pharma, Inc.$100
  • plus $475 from 12 others

What the payments were for

  • Travel & lodging$81236%
  • Food & beverage$1,23655%
  • Education$2139%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,261 in reported general payments places this provider in the 40th percentile of 139 urology providers in Kentucky.

See all urology providers in Kentucky

Medicare billing

Part B allowed, 2024
$119,762
Medicare patients
354
Services billed
2,593

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiaflexCollagenase Clostridium Hist.13$177,438
XtandiEnzalutamide11$153,801
GemtesaVibegron26$28,971
Tamsulosin Hcl329$3,364
Potassium Citrate ErPotassium Citrate26$2,853
Testosterone32$2,709
Testosterone Cypionate90$2,590
Bicalutamide61$2,174
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc13$1,295
Methenamine Hippurate22$1,215
Finasteride60$617
Oxybutynin Chloride ErOxybutynin Chloride29$485
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst14$177
Allopurinol16$167
Cephalexin26$97

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Endo Pharmaceuticals Inc.Xiaflex$209$177,43813 claims
Astellas Pharma US IncXtandi$155$153,80111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 139 urology providers in Kentucky.

Other urology in Elizabethtown

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →